RM-NBS / Neurobehavioural and neuroendocrine signalling
Vasoactive intestinal peptide
Also known as: VIP · Aviptadil
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Vasoactive intestinal peptide is an endogenous neuropeptide. Aviptadil refers to a synthetic presentation used in clinical investigation. Context, route and formulation cannot be collapsed into one generic claim.
Evidence position
Human randomized data supports Grade B. Negative or null findings remain part of the record and are shown rather than filtered out.
What the record does not establish
Clinical-trial material does not authenticate a separate supplier’s sample or support use outside the studied protocol.
Sources
- 01Intravenous aviptadil for COVID-19-associated hypoxaemic respiratory failurePubMed
- Shows
- Randomized placebo-controlled human trial; no significant improvement in the primary outcome
- Does not show
- One clinical setting and controlled formulation; not evidence about unrelated material
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Aviptadil
- CID
- 16132300
- Formula
- C147H237N43O43S
- Mass
- 3326.8
PUBMED / FOUND RECORDS
- Vasoactive intestinal peptide.Journal of endocrinological investigation / 1986 AprPMID 2872248 / DOI 10.1007/BF03348097
- The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine / 2022 Nov 1PMID 36044317 / DOI 10.1097/CCM.0000000000005660
- Aviptadil (Senatek).Current opinion in investigational drugs (London, England : 2000) / 2001 AprPMID 11566015
- Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine / 2023 SepPMID 37348524 / DOI 10.1016/S2213-2600(23)00147-9
- Anticipated pharmacological role of Aviptadil on COVID-19.Environmental science and pollution research international / 2022 FebPMID 34846667 / DOI 10.1007/s11356-021-17824-5
CLINICALTRIALS.GOV / FOUND RECORDS
- Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and SepsisCOMPLETED / PHASE1 / Stony Brook UniversityNCT00004494 / DIRECT intervention MATCH: Vasoactive intestinal peptide
- Vasoactive Intestinal Peptide in COPDCOMPLETED / NO PHASE / Medical University of ViennaNCT00464932 / DIRECT intervention MATCH: Vasoactive intestinal peptide
- Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle PhysiologyCOMPLETED / NO PHASE / Medical College of WisconsinNCT01563757 / DIRECT title MATCH: Vasoactive intestinal peptide
- Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19WITHDRAWN / PHASE3 / APR Applied Pharma Research s.a.NCT05137795 / DIRECT intervention MATCH: aviptadil
- ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)NO_LONGER_AVAILABLE / NO PHASE / APR Applied Pharma Research s.a.NCT04453839 / DIRECT intervention MATCH: aviptadil